India Glycols Limited · NSE:INDIAGLYCO
India Glycols — Q3 FY2022-23 Earnings Presentation
31 slides from India Glycols's earnings presentation, Feb 10, 2023
Slide 1: Regulation 30 disclosure cover letter
10th February, 2023 The Manager (Listing) The Manager (Listing) BSE Limited National Stock Exchange of India Limited 1st Floor, New Trading Ring, Exchange Plaza, C-1, Block G, Rotunda Building, P.J. Towers, Bandra Kurla Complex, Dalal Street, Mumbai – 400 01 Bandra (East), Mumbai- 400 051 Scrip Code
Slide 2: Investor Presentation Q3 FY 2022-23
India Glycols Limited Positive Impact Bio-based Ingredients and Performance Chemicals v v v Investor Presentation Q3 FY 2022-23
Slide 3: Safe Harbour Statement
Safe Harbour Statement This presentation and the following discussion may contain “forward looking statements” by India Glycols Limited (“IGL” or the company) that are not historical in nature. These forward looking statements, which may include statements relating to future results of operations, f
Slide 4: Q3FY23 Performance
Q3FY23 Performance INDIA GEYCOLS LIMITED:
Slide 5: Performance Overview – Q3FY23 vs Q3FY22
Performance Overview – Q3FY23 vs Q3FY22 Gross Turnover Net Turnover 1524 Cr 554 Cr -13.4 % - 30.4% EBITDA EBITDA Margin 76 Cr 13.6% + 23.7% + 591 bps ⦁ Good EBITDA recovery on the back of improved costs, and mix ⦁ Turnover decline YoY due to discontinued low margin business 4
Slide 6: Performance Overview – 9MFY23 vs 9MFY22
Performance Overview – 9MFY23 vs 9MFY22 Gross Turnover Net Turnover 5026 Cr 2032 Cr +1.6 % -8.7% EBITDA EBITA Margin 219 Cr +13.8 % +13.8% + 210 bps ⦁ Q1 of previous year had the Specialty Chemicals number (which is now a part of Clariant JV) ⦁ Good recovery in EBITDA across sectors, led by EB 5
Slide 7: Highlights – Q3FY23
Highlights – Q3FY23 Business Performance □ Overall good Q3 with recovery in EBIT (up 32 % on YoY basis) though on YoY basis Q3 revenue is down by 30%. EBITDA margin is up by 24% for Q3 (YoY) □ Good recovery for 9M (YoY basis) with EBIT up 17% on YoY basis though revenue is down by 8.5%. EBITDA margi
Slide 8: Highlights – Q3FY23
Highlights – Q3FY23 Other Highlights □ Cost pressures have continued with high international ethanol prices □ Grain Plants commissioned, being run to capacity – helping mitigate impact of huge feedstock price increases. Further capacity expansion being evaluated to become completely Atmanirbhar & im
Slide 9: Business Segment Highlights
Business Segment Highlights Bio-based Specialities and Performance Potable Spirits (PS) Ennature Biopharma (EB) Chemicals (BSPC) □ Q3 EBIT up by 22.3% compared to prior year □ Q3- EBIT up by 28.0%, revenue up by 7.2%, □ Revenue up by 27.4%, EBIT up by 28.6% in Q3 though significant drop in reported
Slide 10: Financial Summary - Consolidated
Financial Summary - Consolidated Particulars (In INR Cr) Q3FY23 Q3FY22 Y-o-Y (%) Q2FY23 Q-o-Q (%) 9MFY23 9MFY22 Y-o-Y (%) Revenue from operations (net of excise) 554 795 (30.4%) 670 (17.3%) 2,032 2,226 (8.7%) Other Income 7 7 (0.4%) 6 11.7% 19 17 16.0% Total Income 561 802 (30.1%) 676 (17.1%) 2,051
Slide 11: Segment Performance - Consolidated
Segment Performance - Consolidated (In INR Cr) Q3FY23 Q3FY22 % YoY Q2FY22 % QoQ 9MFY23 9MFY22 % YoY 8% 4% Bio-based Specialities and Performance Chemicals (BSPC) 22% 58% Net 324 587 (44.8%) 442 (26.7%) 1,315 1,597 (17.6%) Revenue 34% EBIT 30 24 22.3% 28 4.8% 82 77 6.5% 74% % margin 9.2% 4.2% 505 bps
Slide 12: Company Overview
Company Overview INDIA GEYCOLS LIMITED:
Slide 13: IGL at a Glance
IGL at a Glance Go Green Diversified product portfolio Global Standards with inherent synergies Compliance with stringent global 1st in the world to use Innovative Green Technologies to manufacture Bio-based Specialties, Bio-Polymers, standards of plant operations, bio-based ethylene oxide & Potable
Slide 14: Key Milestones
Key Milestones New Grain based Formulation Ethanol plant – Gorakhpur Distillery & Gorakhpur & Kashipur Sulphation Glycol E2 Textile Thiocolchicoside JV Clariant First Distillery EO Purification Bio Polymers | Green Solvents ENA MEG 600 TPD US Subsidiary Nicotine Expansion 1988 1990 1994 1996 2001 20
Slide 15: Portfolio Leading in Bio-based Ingredients and Performance Chemicals
Portfolio Leading in Bio-based Ingredients and Performance Chemicals Bio-based Specialities Segments And Performance Potable Spirits (PS) Ennature Biopharma Chemicals (BSPC) Revenue Mix Net revenue share : 58% Net revenue share : 34% Net revenue share : 8% (Consol. Q3FY23) □ Bio-based Glycols (MEG,
Slide 16: JV with Clariant: Leaders in bio-based ethoxylates and derivatives
JV with Clariant: Leaders in in bio-based ethoxylates and derivatives Promoters Public 1 - Shareholding Combining production and distribution capacity, as 61.01% 1 38.99% 1 on 30th June 2021 the joint venture is establishing to become a leading supplier of renewable materials to the rapidly growing
Slide 17: Leveraging synergies – integrated manufacturing for bio-based products
Leveraging synergies to create value–integrated manufacturing for bio-based products Portable Spirits (PS) Products Potable Spirit Industrial Gas ENA Power Alcohol O2, N2, Ar Brands Division Ind Gr. CO2 Grain O2 ASU EO-CO2 mix Business transferred to JV with Clariant Bio-based Specialities Green And
Slide 18: Manufacturing Capabilities
Manufacturing Capabilities Kashipur Gorakhpur Dehradun 300-acre state of art integrated manufacturing complex 56-acre state of art distillation & bottling complex 160,000 sqft state of art facility Fermentation – Molasses and Grain Based Grain based Ethanol High Purity Extraction Ethanol Distillatio
Slide 19: R&D: Creating value through New Product Development
R&D: Creating value through New Product Development; focus on Green Chemistry 1 Focus on NPD, designing products for the future in collaboration with our reputed customers 2 DSIR Recognized R&D at Dehradun and Kashipur 3 Exploiting available feed stocks of Bio-Alcohol, Smart Alcohol, Ethylene Oxide,
Slide 20: Business Segments
Business Segments
Slide 21: Bio-based Specialities and Performance Chemicals (BSPC)
Bio-based Specialities and Performance Chemicals (BSPC) First in the world to manufacture ethylene oxide and glycols from bio-based feedstocks e.g. Molasses, Grain Largest manufacturer of Bio-based glycols and Bio-based Ethylene Oxide made from renewable feedstock i.e. Molasses Products for a
Slide 22: Potable Spirits
Potable Spirits License for operations and sale of Country Liquor in the States of Uttar Pradesh and Uttarakhand. Also operates and sells Indian Made Foreign Liquor (“IMFL”) from its own unit and few tie-up units Company brands are available in the states of Uttarakhand, Uttar Pradesh, Delhi and
Slide 23: Ennature Biopharma
Ennature Biopharma Operates in the space of Nutraceuticals, Phytochemicals & health supplement ingredients. One of the leaders in Complex phytochemicals chemistry in India Global leader in Thiocolchicoside, a highly potent muscle relaxant API Advanced production capabilities, including organic
Slide 24: IGL - Catering to diverse end markets
IGL - Catering to diverse end markets • Glycols are used for the manufacture of polyester yarn, fibre, film and resin and as an automobile coolant • Bio-glycols cater to the beverage and food industry's packaging requirement of PET bottles and polyester film • Ethyl / Butyl glycol ethers and its ace
Slide 25: Growth Drivers
Growth Drivers High prospects of growth of industry sectors being serviced by IGL – Personal Care, Automotive, Packaging, Beverages, Oil & Gas, Home Care, Pharma, Nutraceuticals etc, Textiles – most expected to grow at near double digit or more Increasing consumer awareness and demand for sustai
Slide 26: Yearly financial Performance
Yearly financial Performance
Slide 27: 3-year Financial Trajectory - Consolidated
3-year Financial Trajectory - Consolidated In INR Cr Net Revenue (Excl. Discontinued Biz.) EBITDA (Excl. Discontinued Biz.) PAT (Excl. Discontinued Biz.) 330 2,744 2,890 288 283 277 2,332 109 75 FY2020 FY2021 FY2022 FY2020 FY2021 FY2022 FY2020 FY2021 FY2022 EBITDA (Incl. Discontinued Biz.) PAT (Incl
Slide 28: 3-year Financial Trajectory - Consolidated
3-year Financial Trajectory - Consolidated EBITDA Margin (%) (Excl. Discontinued Biz.) Net Margin (%) (Excl. Discontinued Biz.) RoE (%) 11.4% 12.1% 10.5% 19.2% 9.6% 4.7% 11.1% 11.3% 2.7% FY2020 FY2021 FY2022 FY2020 FY2021 FY2022 FY2020 FY2021 FY2022 EBITDA Margin (%) (Incl. Discontinued Biz.) PAT Ma
Slide 29: Sustainability, ESG and Certifications
Sustainability, ECG and Certifications
Slide 30: Sustainability, ESG
Sustainability, ESG Environment Stewardship • World’s first and largest producer of Bio-Based EO and its derivatives • Next Generation CarbonSmart products from emissions (fossil carbon) - collaboration with Transparent Accountable LanzaTech & consumer majors like Unilever and Lululemon • Environmen
Slide 31: Thank you
Thank you India Glycols Limited CIN: L24111UR1983PLC009097 EY LLP Ankur Jain Company Secretary & Compliance Officer Runjhun Jain Head office runjhun.jain1@in.ey.com Neha S Shroff 2B, Sector-126, Noida Tel: +91-120-6860000, 3090100, 3090200 neha.shroff@in.ey.com Gautam Budh Nagar Fax: +91-120-3090111